Ovarian carcinoma with thyroid metastases causing clinical hypothyroidism: a case report.

Gynecol Oncol

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, CC-913, Boston, MA 02215, USA.

Published: August 2006

Background: Ovarian cancer is known to metastasize to the thyroid gland. Despite an incidence of ovarian metastasis to the thyroid of 3-15%, clinical hypothyroidism resulting from such metastasis has not yet been reported. We present a case of metastatic ovarian cancer to the thyroid resulting in clinical hypothyroidism.

Case: A 55-year-old woman with recurrent papillary adenocarcinoma of the ovary presented with fatigue, abdominal distention, lymphedema, and depression. Thyroid stimulating hormone was markedly elevated, and thyroid biopsy demonstrated bilateral metastatic ovarian carcinoma.

Conclusion: Although uncommon, metastatic disease to the thyroid should be considered when evaluating a patient with advanced ovarian cancer and clinical hypothyroidism.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2006.02.018DOI Listing

Publication Analysis

Top Keywords

clinical hypothyroidism
12
ovarian cancer
12
metastatic ovarian
8
thyroid
7
ovarian
6
ovarian carcinoma
4
carcinoma thyroid
4
thyroid metastases
4
metastases causing
4
clinical
4

Similar Publications

Background: Previous studies showed sex differences in the prevalences of both major depressive disorder (MDD) and subclinical hypothyroidism (SCH). This study aimed to further compare the prevalence and correlates of moderate-to-severe SCH between male and female Chinese MDD patients.

Methods: A total of 1706 first-episode drug naïve Chinese patients with MDD were recruited.

View Article and Find Full Text PDF

Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction.

Endocrine

January 2025

Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.

Purpose: To investigate the relationship between platelet-to-lymphocyte ratio (PLR) or neutrophil-to-lymphocyte ratio (NLR) and Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction.

Methods: This was a single-center retrospective observational study of patients with solid tumors receiving ICI therapy. Clinical characteristics of patients were assessed at baseline and during ICI therapy.

View Article and Find Full Text PDF

Background: Hyperthyroid cats that are azotemic and hypothyroid after surgical or medical treatment have poor outcomes, and supplementation with levothyroxine (LT4) improves survival. However, the effect of LT4 supplementation on survival of nonazotemic, hypothyroid radioiodine (RI)-treated hyperthyroid cats is unknown.

Hypothesis: Radioiodine treated hyperthyroid cats with iatrogenic hypothyroidism or azotemia have shorter survival times than euthyroid, nonazotemic cats and supplementation of LT4 improves survival times of hypothyroid cats.

View Article and Find Full Text PDF

Background: Small-cell lung cancer (SCLC) is highly malignant. Despite being highly sensitive to initial chemotherapy and radiotherapy, the recurrence rate is high. Atezolizumab is the first immune checkpoint inhibitor (ICI) that has been proven to provide an overall survival (OS) benefit for extensive-stage SCLC (ES-SCLC), making ICIs in combination with chemotherapy the standard first-line treatment for ES-SCLC.

View Article and Find Full Text PDF

Background: Thyroid hormones are important in regulating hematopoiesis. Recent research has suggested that red cell distribution width (RDW) and mean platelet volume (MPV) may be useful inflammatory markers in various disorders, including thyroid disorders. Hence, the study aimed to evaluate the association between hypothyroidism, RDW, and MPV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!